In May, Amgen (NASDAQ: AMGN) revealed intriguing data from the first-ever human trial of a drug that targets tumors with a specific mutation to the gene KRAS, which occurs in about one-quarter of all cancers.

Amgen showed 30 percent of lung cancer patients with the mutation saw their tumors shrink. Even though the data were early, the news was significant: KRAS is part of a larger gene family, RAS, that has long proven undruggable.

Now another company going after RAS-driven cancer is riding the wave of momentum. Revolution Medicines has raised a $100 million Series C to advance its own… Read more »